Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Menu
Stocks | Futures | Watchlist | More
 
No Matching Results
Advanced search
or
Site News
Market: Market:

Adverum Biotechnlgs (ADVM)

Adverum Biotechnlgs (ADVM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Alerts
Watch
Help
Go To:
Adverum Biotechnologies Granted Priority Medicines (PRIME) Designation by European Medicines Agency for ADVM-022 in Wet AMD Globe Newswire - Fri Jun 24, 7:00AM CDT

REDWOOD CITY, Calif., June 24, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting...

ADVM : 1.1800 (-1.67%)
Adverum Biotechnologies Announces New Data at the Macula Society’s 2022 Annual Meeting Globe Newswire - Thu Jun 2, 3:05PM CDT

- OPTIC study of intravitreal gene therapy with ADVM-022 (AAV.7m8-aflibercept) for wet AMD shows therapeutic levels of aflibercept out to three years- New...

ADVM : 1.1800 (-1.67%)
Adverum Biotechnologies Presents Research Pipeline Data Supporting Utility of its Proprietary Platform and AAV.7m8 Capsid in Ocular Gene Therapy Globe Newswire - Thu May 19, 7:00AM CDT

REDWOOD CITY, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting...

ADVM : 1.1800 (-1.67%)
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire - Mon May 9, 3:05PM CDT

REDWOOD CITY, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting...

ADVM : 1.1800 (-1.67%)
Adverum Biotechnologies Announces Upcoming Data Presentations at ASGCT 2022 Globe Newswire - Mon May 2, 3:30PM CDT

REDWOOD CITY, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting...

ADVM : 1.1800 (-1.67%)
Adverum Biotechnologies Presents Additional Efficacy and Safety Data from the OPTIC Trial of ADVM-022 in Wet AMD at the ARVO 2022 Annual Meeting Globe Newswire - Sun May 1, 1:15PM CDT

- Poster highlights analysis of baseline neutralizing antibodies to AAV.7m8 and impact on ADVM-022 efficacy and safety in OPTIC - - Reductions in mean...

ADVM : 1.1800 (-1.67%)
Adverum Biotechnologies Announces Upcoming Data Presentations at ARVO 2022 Globe Newswire - Tue Apr 19, 5:00PM CDT

Szilárd Kiss, M.D. to present new post-hoc analyses from the Phase 1 OPTIC Trial of ADVM-022 (AAV.7m8-aflibercept) in wet AMD...

ADVM : 1.1800 (-1.67%)
Adverum (ADVM) Up on FDA Feedback for Gene Therapy Study Zacks - Thu Apr 7, 1:50PM CDT

Adverum (ADVM) to submit IND amendment to the FDA by mid-2022 for starting a mid-stage study on its gene therapy candidate ADVM-022 for treating wet AMD eye disorder.

VYGR : 6.08 (+2.88%)
ADVM : 1.1800 (-1.67%)
TRVI : 2.92 (+3.91%)
AXLA : 2.12 (+4.43%)
Adverum Biotechnologies Proceeds with IND Amendment for ADVM-022 Phase 2 Trial in Wet AMD After Receiving Requested Type C Meeting Feedback from the FDA Globe Newswire - Wed Apr 6, 3:05PM CDT

Company anticipates completing IND amendment process by mid-2022 to enable dosing of the first patient in the planned Phase 2 trial during Third Quarter of...

ADVM : 1.1800 (-1.67%)
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2021 Financial Results Globe Newswire - Tue Mar 29, 3:05PM CDT

REDWOOD CITY, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting...

ADVM : 1.1800 (-1.67%)

Barchart Exclusives

Omega Healthcare Investors Is a Stable Dividend REIT with a 9.3% Yield Barchart - Mon Jul 4, 1:21PM CDT
Omega Healthcare Investors (OHI) invests in long-term healthcare assets, primarily in skilled nursing and assisted living facilities. It has a very stable dividend, which now yields 9.3% with good covered call plays. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' : 'America/Chicago' ]] CDT
Reserve Your Spot